Sermorelin
Sermorelin structure
|
Common Name | Sermorelin | ||
|---|---|---|---|---|
| CAS Number | 86168-78-7 | Molecular Weight | 3357.882 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C149H246N44O42S | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
|
Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice
Behav. Brain Res. 233(1) , 232-6, (2012) Highlights ► The involvement of transmitters in the anxiolytic action of GH-RH antagonist, MZ-4-71, has been tested in plus maze. ► In the experiments the animals were pretreated with phenoxybenzamine, prazosin, yohimbine, methysergide,cyproheptadine and bicu... |
|
|
Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Int. J. Cancer 132(4) , 755-65, (2013) New approaches are needed to the therapy of advanced prostate cancer. This study determined the effect of growth hormone-releasing hormone (GHRH) antagonists, JMR-132 and JV-1-38 on growth of PC3 tumors as well as on angiogenesis and metastasis through the ev... |
|
|
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Cancer 118(3) , 670-80, (2012) Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancer cell lines and experimental tumors by mechanisms that include direct action on GHRH receptors in cancer cells.In this study, the effects of newly synthesi... |
|
|
Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice.
Behav. Brain Res. 224(1) , 155-8, (2011) The growth hormone-releasing hormone (GH-RH) antagonist MZ-4-71 has been shown to suppress secretion of GH and insulin-like growth factor-1 (IGF-1) secretion. These findings suggested that GH-RH antagonists could be used for the therapy of disorders character... |
|
|
Growth hormone releasing hormone (GHRH) signaling modulates intermittent hypoxia-induced oxidative stress and cognitive deficits in mouse.
J. Neurochem. 127(4) , 531-40, (2013) Intermittent hypoxia (IH) during sleep, such as occurs in obstructive sleep apnea (OSA), leads to degenerative changes in the hippocampus, and is associated with spatial learning deficits in adult mice. In both patients and murine models of OSA, the disease i... |
|
|
Growth hormone releasing hormone induces the expression of nitric oxide synthase.
J. Cell. Mol. Med. 15(5) , 1148-55, (2011) Growth hormone releasing hormone (GHRH) and its receptors are expressed in a wide variety of human tumours and established cancer cell lines and are involved in carcinogenesis. In addition, GHRH antagonists exert an antitumour activity in experimental cancer ... |
|
|
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Cell Cycle 11(22) , 4203-10, (2012) Treatment of colon cancer with an antagonist of growth hormone-releasing hormone (GHRH), JMR-132, results in a cell cycle arrest in S-phase of the tumor cells. Thus, we investigated the effect of JMR-132 in combination with S-phase-specific cytotoxic agents, ... |
|
|
Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning.
Behav. Brain Res. 233(2) , 326-30, (2012) The antagonist MZ-4-71 of growth hormone-releasing hormone (GH-RH) has been shown to suppress the secretion of GH and insulin-like growth factor-1 (IGF-1), suggesting that this class of analogs could be used for the therapy of disorders characterized by exces... |
|
|
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Peptides 37(1) , 63-8, (2012) Lung cancers which show increased vascularization and high microvessel density are considered highly metastatic and with poor prognosis. Growth hormone releasing hormone (GHRH) antagonists are anticancer agents without adverse events in lung cancer tumor mode... |
|
|
GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells.
Cell Cycle 10(21) , 3714-8, (2011) AMP-activated protein kinase (AMPK) regulates cellular proliferation, growth and metabolism. Targeted activation of AMPK is considered an important therapeutic strategy for cancer treatment. To evaluate the effect of growth hormone-releasing hormone (GHRH) an... |